Aspire Biopharma Holdings Inc. will participate in the Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference on October 8-9, 2025. The company will present updates on its disruptive sublingual drug delivery technology, including its lead programs targeting FDA submission for sublingual high-dose aspirin and a sublingual ED medication in the second half of 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1081391) on October 03, 2025, and is solely responsible for the information contained therein.